Contact
Please use this form to send email to PR contact of this press release:
Vidac Pharma Receives Renewed “Buy” Rating from Sphene Capital Following German Authorization for New Phase 2 AK Trial
TO:
Max Herzberg
Vidac pharma Holding Plc
+972 54-425-7381